Amgen (AMGN) Cost of Revenue (2009 - 2026)

Amgen has reported Cost of Revenue for 18 years, with the latest figure at $2.8 billion in Q2 2026.

• On a quarterly basis, Cost of Revenue fell 6.64% year-over-year to $2.8 billion in Q2 2026; TTM through Jun 2026 was $11.6 billion, a 6.35% decrease from a year earlier, with the FY2025 full-year figure at $12.0 billion, down 6.39% from the prior year.
• Cost of Revenue was $2.8 billion for Q2 2026 at Amgen, up from $2.7 billion in the prior quarter.
• The five-year high for Cost of Revenue was $3.3 billion in Q3 2024, with the low at $1.5 billion in Q2 2022.
• Average Cost of Revenue over 5 years is $2.5 billion, with a median of $2.9 billion recorded in 2025.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue retreated 7.76% in 2022, then jumped 86.05% in 2024.
• Over 5 years, Cost of Revenue stood at $1.7 billion in 2022, then surged by 78.13% to $3.1 billion in 2023, then changed by 0.0% to $3.1 billion in 2024, then declined by 4.37% to $3.0 billion in 2025, then fell by 5.54% to $2.8 billion in 2026.
• The last three Cost of Revenue figures came in at $2.8 billion (Q2 2026), $2.7 billion (Q1 2026), and $3.0 billion (Q4 2025), per Business Quant data.